Observational analysis shows low cystine levels correlate with severe stroke outcomes in patients, suggesting potential biomarker utility.
Background/Objectives: The amino acid cysteine (Cys) plays an important role in the neuronal injury process in stroke. Cys is present in blood plasma in various forms. The relationship between Cys and its forms and the severity of acute stroke has not been sufficiently studied. We investigated the total Cys and the levels of two of its forms (reduced Cys and its disulfide (cystine, CysS)) in blood plasma and the influence on stroke severity in patients at admission. Methods: A total of 210 patients (39-59 years old) with ischemic stroke and intracerebral or subarachnoid hemorrhage were examined. The content of the different forms of Cys was determined in the first 10–72 h. Stroke severity was estimated using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRs). Results: CysS levels < 54 μM were associated with severe (NIHSS>13) neurological deficit (ischemic stroke: RR=5.58, p=0.0021; hemorrhagic stroke: RR=3.56, p=0.0003). Smoking and high levels of total Cys and other thiols (glutathione and homocysteine) appear to be factors determining this relationship. Conclusions: Low CysS levels may act as a potential biomarker of acute stroke severity.
No takes yet. Share an insight, caveat, or question.
Ivanov et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: